title: Use of dried blood spots in drug development: pharmacokinetic considerations.
abstract: Dried blood spots are increasingly being used in drug development. This commentary considers the pharmacokinetic issues that arise and compares these with those attached to plasma, the mainstay matrix. A common implicit use of these matrices is as a surrogate for plasma water, and to this extent, the critical assumption made is constancy in fraction unbound for plasma and, additionally for blood, constancy of hematocrit and blood cell affinity of compound. Often, these assumptions are reasonable and either matrix suffices, but not always. Then the value of one over the other matrix depends on the magnitude of the blood-to-plasma concentration ratio of drug, its clearance, and the cause of the deviation from constancy. Additional considerations are the kinetics of distribution within blood and those arising when the objective is assessment or comparison of bioavailability. Most of these issues can be explored and addressed in vitro prior to the main drug development program.
authors.affiliation: Centre for Applied Pharmacokinetic Research, School of Pharmacy & Pharmaceutical Sciences, Stopford Building, University of Manchester, Manchester M139PT, UK. MRow190539@aol.com
authors.forename: Malcolm
authors.initials: M
authors.lastname: Rowland
authors.forename: Gary T
authors.initials: GT
authors.lastname: Emmons
mesh_terms: D001769:Blood; D015195:Drug Design; D006801:Humans; D010599:Pharmacokinetics
references.citation: J Pharm Biomed Anal. 2007 Jul 27;44(3):658-64
references.pmid: 17184953
references.citation: J Clin Lab Anal. 1991;5(1):74-7
references.pmid: 1999766
references.citation: Clin Chim Acta. 2006 Nov;373(1-2):27-31
references.pmid: 16797519
references.citation: J Pharmacokinet Biopharm. 1977 Aug;5(4):359-75
references.pmid: 894487
references.citation: J Pharm Sci. 1972 Jan;61(1):70-4
references.pmid: 5019220
references.citation: Anal Bioanal Chem. 2009 Jun;394(4):1171-82
references.pmid: 19387621
references.citation: Pharm Res. 1988 Feb;5(2):80-5
references.pmid: 3073383
references.citation: Anal Chem. 2009 Feb 15;81(4):1557-63
references.pmid: 19154107
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 15;877(8-9):799-806
references.pmid: 19237324
references.citation: Ther Drug Monit. 2009 Jun;31(3):327-36
references.pmid: 19349929
references.citation: J Pharm Sci. 1993 Mar;82(3):340-1
references.pmid: 7680714
references.citation: J Pharm Biomed Anal. 2009 Nov 1;50(4):664-70
references.pmid: 19155152
references.citation: J Pharm Sci. 2005 Jun;94(6):1259-76
references.pmid: 15858854
references.citation: Biomed Chromatogr. 2010 Jan;24(1):49-65
references.pmid: 20017122
references.citation: J Pharmacokinet Biopharm. 1994 Oct;22(5):327-65
references.pmid: 7791036
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):32-7
references.pmid: 18550454
references.citation: J Pharm Biomed Anal. 2009 Feb 20;49(2):393-400
references.pmid: 19059744
references.citation: Pediatrics. 1963 Sep;32:338-43
references.pmid: 14063511
references.citation: Pharm Res. 2007 May;24(5):918-33
references.pmid: 17372687
references.citation: Demography. 2007 Nov;44(4):899-925
references.pmid: 18232218
references.citation: J Pharm Biomed Anal. 2009 May 1;49(4):1034-9
references.pmid: 19269771
references.citation: J Pharmacol Exp Ther. 1998 Nov;287(2):457-68
references.pmid: 9808668
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):153-8
references.pmid: 15282106
references.citation: J Nutr. 2001 May;131(5):1631S-6S
references.pmid: 11340130
references.citation: Clin Biochem. 2005 Jun;38(6):552-7
references.pmid: 15885236